CATALYST PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.94 USD | +1.85% |
|
+8.29% | -5.18% |
| May. 10 | HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating | MT |
| May. 09 | Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Presenter SpeechBrian Elsbernd (Executives)Good morning, and welcome to the 2023 Annual Meetin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.94
USD
Average target price
27.29
USD
Spread / Average Target
+71.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.18% | 1.88B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Transcript : Catalyst Pharmaceuticals, Inc. - Shareholder/Analyst Call